Table 2 Correlation between clinical features and short-term efficacy in 39 patients with non-small cell lung cancer.
Quantity | CR | PR | SD | PD | ORR | ORR (P value) | DCR | ORR (P value) | |
|---|---|---|---|---|---|---|---|---|---|
Sex | |||||||||
Male | 28 | 1 | 8 | 11 | 8 | 32.1% | 0.461 | 71.4% | 0.709 |
Female | 11 | 0 | 2 | 5 | 4 | 18.2% | 63.6% | ||
Age | |||||||||
< 70 | 29 | 1 | 6 | 10 | 12 | 24.1% | 0.424 | 58.6% | 0.017 |
≥70 | 10 | 0 | 4 | 6 | 0 | 40.0% | 100% | ||
ECOG PS scores | |||||||||
0 | 17 | 1 | 3 | 8 | 5 | 23.5% | 0.484 | 70.6% | 0.388 |
1 | 19 | 0 | 7 | 7 | 5 | 36.8% | 73.7% | ||
2 | 3 | 0 | 0 | 1 | 2 | 0% | 33.3% | ||
Stage | |||||||||
III | 11 | 1 | 4 | 3 | 3 | 45.5% | 0.426 | 72.7% | 0.072 |
IVA | 18 | 0 | 4 | 11 | 3 | 22.2% | 83.3% | ||
IVB | 10 | 0 | 2 | 2 | 6 | 20.0% | 40.0% | ||
Smoking history | |||||||||
Never | 12 | 0 | 2 | 8 | 2 | 16.7% | 0.725 | 83.3% | 0.168 |
Yes | 27 | 1 | 8 | 8 | 10 | 33.3% | 62.9% | ||
Pembrolizumab initiation (line of therapy) | |||||||||
1 | 26 | 1 | 7 | 10 | 8 | 30.8% | 0.625 | 66.7% | 0524 |
2 | 7 | 0 | 1 | 3 | 3 | 14.3% | 60.0% | ||
≥3 | 6 | 0 | 2 | 2 | 2 | 33% | 87.5% | ||
PD-L1 status | |||||||||
Positive | 19 | 0 | 5 | 8 | 6 | 26.3% | 0.800 | 68.4% | 0.787 |
Negative/Unknown | 20 | 1 | 5 | 8 | 6 | 30.0% | 70.0% | ||
Histological subtype | |||||||||
Adenocarcinoma | 18 | 0 | 5 | 7 | 6 | 26.3% | 0.969 | 68.4% | 0.763 |
Non-Adenocarcinoma | 21 | 2 | 6 | 8 | 5 | 30.0% | 70.0% | ||
